Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 12, Number 10—October 2006


Active Surveillance of Candidemia, Australia

Sharon Chen*Comments to Author , Monica Slavin†, Quoc Nguyen‡, Deborah Marriott‡, E. Geoffrey Playford§, David Ellis¶, Tania Sorrell*#, and the Australian Candidemia Study
Author affiliations: *Westmead Hospital, Westmead, New South Wales, Australia; †Royal Melbourne Hospital, Melbourne, Victoria, Australia; ‡St. Vincent's Hospital, Sydney, New South Wales, Australia; §Princess Alexandra Hospital, Brisbane, Queensland, Australia; ¶Women's and Children's Hospital, Adelaide, South Australia, Australia; #University of Sydney, Sydney, New South Wales, Australia

Main Article

Table 4

Multivariate predictors of death by candidemia 30 days after diagnosis, Australia, 2001–2004*

Characteristic OR 95% CI p value
Age >65 y 3.0 2.0–4.3 <0.001
ICU stay 3.2 2.1–5.0 <0.001
Corticosteroid therapy 2.8 1.9–4.1 <0.001
Hemodialysis 2.4 1.4–4.1 0.002
Hyperalimentation 1.7 1.1–2.5 0.006
Antimicrobial drug use 2.1 0.9–4.4 0.07
Neutropenia 2.2 1.3–3.6 0.002
Sepsis present 3.1 1.7–5.4 <0.001
Treatment with antifungal agent 0.01 0.06–0.2 <0.001
Candida glabrata infection 1.8 1.1–2.9 0.01

*Sixteen candidate variables were included in the final model. OR, odds ratio; CI, confidence interval; ICU, intensive care unit.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO